COMMONWEALTH OF AUSTRALIA
Department of Health
Therapeutic Goods Administration
THERAPEUTIC GOODS ACT 1989
Section 14 and 14A Notice
On May 20 2014, the delegate of the Secretary of the Department of Health for the purposes of subsection 14 and 14A of the Therapeutic Goods Act 1989 (“the Act”), by application of Aspen Pharmacare Australia Pty Ltd, gave consent to:
The importation and supply of danaparoid sodium (ORGARAN) 750 anti-Xa units per 0.6 mL injection ampoule [AUST R 46096] that does not conform with the requirements of paragraph 3(2)(l) of the Therapeutic Goods Order No. 69- General requirements for labels for medicines in that the labels state the previous sponsor contact details.
The consent is effective from May 20, 2014 until May 20, 2015.
The delegate of the Secretary has, under subsection 15(1) of the Act, made the consent subject to the following conditions:
- The labels are those currently supplied which state the previous sponsor;
- Arrangements are in place to redirect all correspondence to the current sponsor (Aspen); and
- No other changes have been made.